Takeda Pharmaceutical Company Limited
TKPHF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$59.99B
Close$
$46.29
21.9% upside
Current Fair Value
21.9% upsideUndervalued by 21.9% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $59.99 Billion |
|---|---|
| Enterprise Value | $4.66 Trillion |
| Annual dividend | $1.28 |
| Dividend yield | 3.16% |
| Earnings per Share | $123.03 |
| Beta | 0.09 |
| Outstanding Shares | 1,579,922,000 |
Return
| Return on Equity | 2.41% |
|---|---|
| Return on Assets | 1.16% |
| Return on Invested Capital | 5.02% |
Valuation & Multiples
| P/E Ratio | 55.94 |
|---|---|
| PEG | -629.15 |
| Price to Sales | 0.01 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | 1 |
| Enterprise Value to EBIT | 7.19 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 1.09 |
| Debt to Equity | 0.67 |
Revenue Sources
No data
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.33
Consensus analyst estimateRevenue Estimate
$7.07 B
Consensus analyst estimateNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$0.29
Consensus analyst estimateRevenue Estimate
$7.35 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Takeda Pharmaceutical Co
47,029 employees
CEO: Christophe Weber
Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the Unite...